(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Xinan Sheng discussing the phase II RC48-C017 trial assessing neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer with HER2 expression.
Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is recommended for the cisplatin-eligible patients with muscle invasive bladder cancer. Immunotherapy based neoadjuvant therapy has a significant impact on the treatment of most cancers. For example, the NIAGARA study demonstrated that neoadjuvant durvalumab + chemotherapy significantly improved event free survival and overall survival in operable muscle invasive bladder cancer. There are several clinical trials that combine…